A Phase III randomized, open-label study of pasritamig (JNJ-78278343), a T-cell-redirecting agent targeting human kallikrein 2, with docetaxel versus docetaxel for metastatic castration-resistant prostate cancer

http://isrctn.com/ 2026 Dataset

View at publisher

Authors: Peter Chatfield, Johann De Bono

DOI: 10.1186/isrctn12271587

Cited by: 0

Publication details

Journal / source: http://isrctn.com/
Publication date: 9 January 2026
Document type: Dataset